Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983409 | 0.83 | ADRA1D (0.34) | TYMPADRA1DADRA1AADRA1B | |
| SCHEMBL4348692 | 0.82 | ADRA1D (0.37) | TYMPADRA1DADRA1AADRA1B | |
| SCHEMBL4347789 | 0.81 | TYMP (0.31) | TYMPADRA1DADRA1AADRA1B | |
| SCHEMBL26787539 | 0.80 | ALDH1A1 (0.44) | TYMPADRA1DADRA1AADRA1B | |
| SCHEMBL11580947 | 0.79 | ALDH1A1 (0.36) | TYMP | |
| SCHEMBL10618040 | 0.78 | ADRA1D (0.33) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6421372 | 0.78 | HASPIN (0.31) | ADRA1DADRA1AADRA1B | |
| SCHEMBL1923337 | 0.78 | CYP1A2 (0.44) | — | |
| SCHEMBL8377755 | 0.78 | TYMP (0.32) | TYMPADRA1DADRA1AADRA1B | |
| SCHEMBL8377767 | 0.78 | ADRA1D (0.31) | ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137486-A1 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | HELIX NANOTECHNOLOGIES INC (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250206770-A1 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | HELIX NANOTECHNOLOGIES INC | 2025-06-26 | — | — | US | claimed |
| EP-4337331-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | The Broad Institute Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4314332-A2 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | ModernaTX, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-109804083-B | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2023-11-03 | — | — | CN | claimed |
| EP-4133111-A1 | DEVICE AND METHOD FOR PHOTOTHERMAL ENHANCED PLASMONIC BIOSENSING | EMPA Eidgenössische Materialprüfungs- und Forschungsanstalt (CH) | 2023-02-15 | — | — | EP | claimed |
| US-20220315972-A1 | SINGLE PRIMER TO DUAL PRIMER AMPLICON SWITCHING | SIGMA ALDRICH CO LLC (US) | 2022-10-06 | — | — | US | claimed |
| US-11390913-B2 | Single primer to dual primer amplicon switching | SIGMA-ALDRICH CO. LLC (US) | 2022-07-19 | — | — | US | claimed |
| US-20210332078-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION | Twist Bioscience Corporation | 2021-10-28 | — | — | US | claimed |
| EP-3252166-B1 | PREPARATION METHOD FOR AEROMONAS LYSINE NANO-PORE CHANNEL AND APPLICATION THEREOF | UNIV EAST CHINA SCIENCE & TECH (CN) | 2020-08-26 | — | — | EP | claimed |
| US-20160333340-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION | Twist Bioscience Corporation | 2016-11-17 | — | — | US | claimed |
| US-20150093752-A1 | Conversion of alpha-hydroxyalkylated residues in biomolecules using methyltransferases | VILNIUS UNIVERSITY (LT) | 2015-04-02 | — | — | US | claimed |
| WO-2008033432-A2 | IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1282639-A2 | POLYAMIDE NUCLEIC ACID DERIVATIVES, AGENTS AND METHODS FOR PRODUCING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2003-02-12 | — | — | EP | claimed |
| WO-2001079249-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH A NEGATIVE CHARGE, AGENTS AND METHODS FOR PRODUCING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-10-25 | — | — | WO | claimed |
| WO-2001068807-A2 | IDENTIFICATION OF IN VIVO DNA BINDING LOCI OF CHROMATIN PROTEINS USING A TETHERED NUCLEOTIDE MODIFICATION ENZYME | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2001-09-20 | — | — | WO | claimed |
| EP-0934521-A1 | IN VITRO ASSAY FOR CARCINOGENS USING PHENOTYPIC TRANSFORMATION OF HUMAN CELLS | Viratest Carcinogen Monitoring, Ltd. (CA) | 1999-08-11 | — | — | EP | claimed |
| US-5763180-A | In vitro assay for carcinogens using phenotypic transformation of human cells | VIRATEST CARCINOGEN MONITORING LTD. (CA) | 1998-06-09 | — | — | US | claimed |
| WO-1998007030-A1 | IN VITRO ASSAY FOR CARCINOGENS USING PHENOTYPIC TRANSFORMATION OF HUMAN CELLS | VIRATEST CARCINOGEN MONITORING LTD. (US) | 1998-02-19 | — | — | WO | claimed |
| WO-1993017651-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES, THEIR PRODUCTION AND USE | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 1993-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206770-A1 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | RNGTT, RNMT, NSUN2 | TYMP 580/4885ADRA1D 4807/4885ADRA1A 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.